All In Biotech

Drug Trial Radar · NCT02691299

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Treated With Fruquintinib

Last checked: Nov 20, 2026Latest source record: Feb 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 527 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

527

Actual

Start

Dec 9, 2015

Primary completion

Sep 21, 2018

Study completion Nov 16, 2018

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
First posted
Feb 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Fruquintinib/Placebo 5 mg, QD, orally administered under fasting conditions for 3 consecutive weeks followed by one-week off to evaluate the survival benefit of patients with advanced non-squamous NSCLC treated with Fruquintinib.

Conditions

  • NSCLC

Interventions

  • FruquintinibDrug

    Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off

  • PlaceboDrug

    Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. overall survival (OS)Time frame: From the date of randomization until the date of death from any cause, Assessed up to 15 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • 307 Hospital of PLA

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Beijing Chest Hospital

    Beijing, Beijing Municipality, China

  • Guangdong General Hospital

    Guangzhou, Guangdong, China

  • Nantong Tumor Hospital

    Nantong, Jiangsu, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Linyi Tumor Hospital

    Linyi, Shandong, China

  • The Cancer Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • West China Hospital

    Chengdu, Sichuan, China

  • The First Affiliated Hosptial of College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.